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Ten patients with squamous cell carcinoma of the cervix met- 
astatic to periaortic lymph nodes were treated with external-beam 
radiation therapy and synchronous infusion of intravenous S- 
liuorouracil (5FU) chemotherapy at doses of 350 mg/m’/day. 
The overall response rate was 90% with four complete responses 
(CR) and five partial responses (PR). The median duration of 
response was 11.8 months for CRs and 3.6 months for PRs. 
Toxicity was tolerable, with gastrointestinal symptoms and my- 
elosuppression being noted most frequently. No patient experi- 
enced life-threatening toxicity. Median survival was 7.6 months, 
with only one patient being alive and free of disease at 2 years. 
In this pilot study we were unable to demonstrate a beneficial 
effect of continuous infusion of low doses of 5-FU chemotherapy 
concurrent with radiation therapy when compared to conventional 
radiotherapy in patients with advanced squamous cell carcinoma 
of the cervix. 0 1992 Academic Press, Inc. 
Chemotherapy administered concurrently with radio- 
therapy has been reported to improve responses in a va- 
riety of tumors that respond to either therapy alone, in- 
cluding cancers arising in the oropharynx, esophagus, 
colon, and cervix [l-4]. The increased responses to ther- 
apy have been attributed to the radiosensitizing properties 
of certain chemotherapeutic agents. Proposed mecha- 
nisms of action for radiation sensitization include shift in 
tumor radiation dose-response curve, inhibition of repair 
of sublethal and potentially lethal radiation-induced dam- 
age, alterations in cell cycle kinetics such that an increased 
proportion of tumors are in a radiosensitive phase, and 
reduction in tumor bulk with subsequent increase in blood 
supply and oxygenation to irradiated tissues [5,6]. 
5-Fluorouracil (5FU) has received particular attention 
as a radiosensitizing agent in both clinical and laboratory 
’ To whom reprint requests should be addressed at Swedish Hospital 
Medical Center, 1229 Madison St. (1050), Seattle, WA 98104. 
studies. In vitro studies indicate that sensitization by 5- 
FU depends on drug concentration and timing of expo- 
sure. It appears that maximum sensitization occurs when 
prolonged low levels of 5-FU are combined with radio- 
therapy [7,8]. The optimum schedule for clinical use is 
yet to be defined; however, most studies to date have 
utilized short, intermittent infusional therapy with rela- 
tively high doses of 5-FU [9-111. We undertook this pilot 
study to evaluate the efficacy of continuous infusion of 
low-dose 5-FU chemotherapy administered concurrently 
during the course of external-beam radiation therapy in 
patients with squamous cell carcinoma of the cervic met- 
astatic to periaortic lymph nodes. These patients have a 
2-year survival of approximately 20% with radiation ther- 
apy alone [12] and therefore stand to benefit significantly 
if a more effective treatment can be identified. 
MATERIALS AND METHODS 
Ten patients with squamous cell carcinoma of the cervix 
metastatic to periaortic nodes were treated at the Uni- 
versity of Michigan Medical Center with combined ra- 
diotherapy and continuous infusion of 5-FU chemother- 
apy from January 1986 to December 1988. Nine patients 
had periaortic nodal disease identified by lymphangio- 
gram or CT scan that was histologically confirmed by 
needle aspiration in eight patients. Needle aspiration was 
unsuccessful in one patient because of obesity. Surgical 
debulking of enlarged nodes was not performed. Micro- 
scopically positive periaortic nodal disease was identified 
in the final patient with negative lymphangiogram and CT 
scan by retroperitoneal periaortic node sampling. All pa- 
tients had large bulky pelvic tumor masses at least 6 cm 
in bidirectional diameters. Eight of ten patients had clin- 
ical stage III or IV disease and one patient had a large 
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TABLE 1 
FIG0 Stage of Treated Patients 
TABLE 3 
Maximum Toxicity 
FIG0 stage GOG grade 
No. of patients 
IA IIB IIIB IVA 
1 1 5 3 
pelvic recurrence (10 x 8 cm) after surgical therapy for 
a microinvasive carcinoma (Table 1). 
External-beam radiation therapy was delivered using 
lo- or 16-MeV linear accelerators. Daily fractions of 180- 
200 cGy were administered Monday through Friday of 
each week. Pelvic radiotherapy was delivered AP-PA to 
doses of 45-50 Gy depending upon tumor response. Pel- 
vic portals were approximately 15 x 15 cm, extending 
to the sacroiliac joints superiorly, the obturator foramina 
inferiorly, and the pelvic sidewalls laterally. Periaortic 
nodes were treated concurrently to a dose of 44-50 Gy 
through midline portals encompassing nodal tissue to the 
bottom of Tll. After completion of external-beam ther- 
apy, brachytherapy was administered using Fletcher-Suit 
applicators. One or two implants were employed de- 
pending on tumor geometry to boost point A doses to 
72-88 Gy. 
Toxicity 1 2 3 4 
Gastrointestinal 1 4 4 - 
Stromatitis - - 1 - 
Granulocytopenia - 2 1 - 
Thrombocytopenia 2 - - - 
greater that 1500 granulocytes/mm3 or 100,000 plate- 
lets/mm3. All toxicity was graded using standard Gyne- 
cologic Oncology Group definitions. 
5-FU, 350 mg/m*, dissolved in 500 cc of D5W, was 
administered as a continuous intravenous infusion (CI) 
over 24 hr on each day of external-beam therapy. Infu- 
sions were begun on Monday prior to the first weekly 
radiation treatment and completed Saturday morning 24 
hr after the last weekly radiation treatment. Central ven- 
ous access was established in all patients to facilitate ad- 
ministration of chemotherapy. Complete blood counts 
were obtained twice weekly and chemotherapy was dis- 
continued for nutropenia less than 1000 granulo- 
cytes/mm3 or thrombocytopenia less than 50,000/mm3. 
Chemotherapy was also withheld if gastrointestinal symp- 
toms that were unresponsive to oral antiemetic or anti- 
diarrhea1 therapy occurred. Radiation therapy was de- 
layed if toxicity persisted despite discontinuation of 
chemotherapy. Therapy was reinstituted without dose re- 
duction once symptoms resolved or counts recovered to 
Patient follow-up consisted of physical examinations 
every 3 to 4 months. Abdominal-pelvic CAT scans were 
performed at the completion of therapy and approxi- 
mately yearly thereafter if residual pelvic disease was not 
identified on physical examination. Clinical response was 
defined as follows: complete response (CR), disappear- 
ance of all clinically measurable disease; partial response 
(PR), a 50% or greater reduction in the size and/or num- 
ber of lesions; progressive disease, a 50% or greater in- 
crease in the size and/or number of lesions; stable disease, 
all patients not meeting any of the above criteria. All 
patients were followed until disease progression or for at 
least 2 years. 
RESULTS 
The overall response rate was 90% (Table 2). Four 
patients achieved a complete response and five patients 
demonstrated a partial response. The pelvic control rate 
was 40%. Pelvic responses appeared to be unrelated to 
pelvic tumor bulk and were noted in seven of eight pa- 
tients with stage III and IV disease. Mean response du- 
ration was 11.8 months for CRs and 3.6 months for PRs. 
Pelvic recurrences were not noted in any patient initially 
achieving local control. 
TABLE 2 
Clinical Response by FIG0 Stage 
Clinical response 
Stage Complete Partial Stable Progressive 
IA - 1 - - 
IIB 1 - - - 
IIIB 1 4 - - 
IVA 2 - - 1 
Chemotherapy was interrupted or discontinued in five 
patients. Reasons for withholding chemotherapy were GI 
toxicity (three patients), GI toxicity and myelosuppres- 
sion (one patient) and stomatitis (one patient) (Table 3). 
For patients not receiving the entire scheduled dose of 
chemotherapy, three patients received greater than 75% 
of the scheduled dose, one patient received 30% of the 
scheduled dose, and one patient received 13% of the 
scheduled dose. Four of nine responders (two CR, two 
PR) were seen in patients with chemotherapy interrupted. 
Radiation therapy was not interrupted in any patients. 
One patient required laparotomy and lysis of adhesions 
for small bowel obstruction 6 months after completing 
therapy. No patient deaths were related to treatment 
toxicity. 
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FIG. 1. Kaplan-Meier survival curve for 10 patients with cervix 
cancer treated with low-dose 5-FU and radiation therapy (median sur- 
vival, 7.5 months). 
Median survival calculated by the method of Kaplan 
and Meier was 7.5 months (Fig. 1). At 2 years following 
treatment, eight patients had died of progressive cancer 
and one patient remained alive and free of disease. One 
patient died of pneumonia 8 months after completing 
therapy and 2 months after laparotomy for small bowel 
obstruction. No tumor was identified at surgery and the 
patient remained clinically free of disease at the time of 
death. An autopsy was not performed. Metastatic tumor 
was identified outside the radiation treatment field in four 
of eight patients who died of disease including two of 
four patients who demonstrated CRs. Sites of distant fail- 
ures included lungs, scalene and para-tracheal lymph 
nodes, liver, bone, and upper abdomen. 
DISCUSSION 
Patients with squamous cell carcinoma metastatic to the 
periaortic nodes respond poorly to conventional treat- 
ment and are good candidates for carefully designed ex- 
perimental protocols. The treatment protocol used in this 
study was based on tumor cell line data reported by By- 
field et al. [7], which demonstrated maximum radiosen- 
sitization when cells are continuously exposed to 5-FU at 
doses within the cytotoxic range. Clinical data have dem- 
onstrated that continuous infusion of 5-FU at doses near 
those used in this study is associated with acceptable tox- 
icity and can achieve serum levels of 5-FU that are cy- 
totoxic to many cell types [13-151. 
The toxicity of continuous-infusion 5-FU and radiation 
therapy has not been thoroughly described. In this study 
overall toxicity was acceptable with only five episodes of 
grade 3 and no grade 4 toxicities noted. The development 
of side effects required the interruption of chemotherapy 
in five patients while radiation therapy was not inter- 
rupted in any patients. Three patients received at least 
75% of the scheduled treatment despite interruption in 
therapy. To date, we have treated eight additional pa- 
tients with cervical adenocarcinoma or endometrial car- 
cinoma with continuous infusion 5-FU (250-350 
mg/m*/day) and radiotherapy and have observed a sim- 
ilar toxicity profile with three grade 3 (gastrointestinal, 
one; granulocytopenia, two) and no grade 4 toxicities 
among these patients. None of our patients have devel- 
oped hand-foot syndrome, skin rashes, or cerebellar 
symptoms. This experience is in contrast to that of Bar- 
bounis et al. [13], Lokich et al. [14], and Huan et al. [15], 
who noted stomatitis and hand-foot syndrome to be 
among the most common complications of CI 5-FU. Pa- 
tients in these series received CI 7 days/week rather than 
5 days/week as used in this study. Preliminary data from 
the M. D. Anderson Hospital [16] have suggested that 
toxicity with CI 5-FU may be modulated with 5-day rather 
than 7-day infusions. Laparotomy for small bowel ob- 
struction was required for one patient in the present series 
and future studies that include prolonged follow-up will 
be necessary to determine if this therapy is associated 
with an increased incidence of late bowel complications. 
Using our treatment protocol we were unable to dem- 
onstrate improved tumor response or patient survival with 
CI 5-FU and radiotherapy over that with radiation ther- 
apy alone [12]. The sample size in this study is small and 
therefore not sensitive to minor differences between our 
treatment approach and conventional therapy; however, 
the pelvic control rate of 40% and 2-year survival of 11% 
noted in this study are less favorable than those in reports 
from many series that have utilized radiation therapy 
alone 117-201 making it unlikely that benefit could be 
demonstrated even with a larger sample size. Addition- 
ally, responses were nearly equally distributed among pa- 
tients receiving the full schedule of chemotherapy and 
those who had chemotherapy interrupted. It might be 
argued that the patient with recurrent microinvasive can- 
cer should be excluded from the response and survival 
data as this tumor may be biologically different from those 
treated at primary diagnosis; however, our results are not 
altered by inclusion of this patient (response rate, 90% 
vs 89%; median survival, 7.5 months vs 7.0 months). 
Clinically the therapeutic benefit of 5-FU appears to 
be related to its dose or scheduling. Byfield et al. have 
demonstrated an increased survival in patients with ad- 
vanced esophageal carcinoma when 5-FU was given in 
doses of 1000 mg/m* daily during split-course radiation 
therapy [3]. Thomas et al. [9], Evans et al. [lo], and 
Ludgate et al. [ll] have demonstrated improved local 
control in patients with advanced gynecologic malignan- 
cies using combinations of 5-FU, mitomycin-C, and split- 
course or conventional radiation therapy, while Ludgate 
et al. [ 1 l] were also able to demonstrate improved patient 
survival. All of these studies utilized 4-day infusions of 
5-FU in the dose range of 1000 mg/m*/day that were 
delivered once or twice during radiation therapy. Given 
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our overall favorable toxicity profile, further studies might 
include CI with doses of 5-FU higher than those used in 
the present study or the use of other agents in addition 
to 5-FU. Weekly 3-day infusions of 5-FU as described by 
Barbounis et al. [13] may allow for dose escalation of 5- 
FU greater than that in 5-day CI protocols. The effect 
of this type of schedule change on the radiosensitizing 
properties of 5-FU is unknown. Potential agents for com- 
bination regimens include &platinum, carboplatinum, 
and bromodeoxyuridine, which experimentally have been 
shown to have radiosentizing properties [21-231. The plat- 
inum compounds are known to have significant cytotox- 
icity against cervical squamous cell cancer [24]. The oc- 
currence of distant failures in our study demonstrates the 
need for chemotherapy combinations that utilize agents 
with cytotoxicity against cervical cancer. It is to be hoped 
that this will increase the control of micrometastatic dis- 
ease, which, even in the presence of radiosensitization of 
known tumor deposits, may remain a major obstacle to 
improving patient survival. 
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